Pfizer’s BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

Pfizer (PFE) announced positive Phase 3 BREAKWATER trial results for BRAFTOVI in combination with cetuximab and mFOLFOX6 as a first-line treatment for metastatic colorectal cancer (mCRC) with BRAF V600E mutation. The regimen showed a statistically significant 51% reduction in the risk of death versus standard-of-care, with median overall survival increasing to 30.3 months compared to 15.1 months; it also reduced the risk of disease progression or death by 47%. These results, simultaneously published in the New England Journal of Medicine, could establish a new standard of care and support full FDA approval.

Analysis

Pfizer Inc. (PFE) has reported statistically significant and clinically meaningful survival results from its Phase 3 BREAKWATER trial for BRAFTOVI® (encorafenib) in combination with cetuximab and mFOLFOX6 for treatment-naïve patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC). The regimen demonstrated a 51% reduction in the risk of death compared to standard-of-care, with median overall survival increasing to 30.3 months versus 15.1 months (HR 0.49, p<0.0001). Furthermore, the trial met its dual primary endpoint of progression-free survival, showing a 47% reduction in the risk of disease progression or death, with median PFS at 12.8 months compared to 7.1 months (HR 0.53, p<0.0001). The objective response rate was also notably higher at 65.7% for the BRAFTOVI combination versus 37.4% for the control arm. These results, presented at ASCO and published in the New England Journal of Medicine, are particularly impactful as they represent the first substantial survival improvements in the first-line setting for this patient subgroup, which constitutes 8-12% of mCRC cases and has a poor prognosis. The BRAFTOVI combination regimen received accelerated FDA approval in December 2024, and these robust survival data are now being discussed with the FDA to support potential conversion to full approval in 2025, potentially establishing it as a new standard-of-care. The safety profile was consistent with known profiles of the individual agents, with no new safety signals identified, though 13.8% of patients discontinued BRAFTOVI due to adverse reactions.

Key Decisions for Investors

• Investors should view these BREAKWATER trial results as a significant positive catalyst for Pfizer, potentially establishing BRAFTOVI as a new standard-of-care for first-line BRAF V600E-mutant mCRC, which could translate to meaningful revenue contribution.
• Monitor closely the upcoming FDA discussions and decision regarding full approval for the BRAFTOVI combination in 2025, as this will be critical for de-risking and realizing the commercial potential of this regimen.
• Consider the strong competitive positioning this data provides Pfizer in a high unmet need segment of oncology, though continue to evaluate the safety profile and discontinuation rates in the context of long-term adoption and market share.